Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Remedee Labs' Endorphin Stimulator for Fibromyalgia Earns Breakthrough Status - Medical Product Outsourcing
OEM News

Remedee Labs’ Endorphin Stimulator for Fibromyalgia Earns Breakthrough Status

New approach can help relieve fibromyalgia patients' pain, sleep disorders, fatigue, and stiffness.

French startup Remedee Labs earned U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its non-pharmaceutical endorphin stimulation technology for fibromyalgia, adjunctively with standard of care.
 
“Achieving Breakthrough Device status for our endorphin stimulator is a major step, one that recognizes its potential for treating fibromyalgia patients’ pain. We look forward to working closely with the FDA to bring our solution to patients in the United States as fast as possible,” David Crouzier, co-founder and CEO of Remedee Labs told the press.
 
Remedee’s technology is a new approach to treating fibromyalgia patients’ pain and can help to relieve pain, sleep disorders, fatigue, and stiffness.
 
The company began a 170-patient multicenter study in France in November to assess its endorphin stimulator’s benefits for treating fibromyalgia. Recruitment ended May 12, and the company expects results early next year.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters